Published 4 days ago • loading... • Updated 4 days ago

1ST Biotherapeutics Joins The Michael J. Fox Foundation’s LITE Program to Advance LRRK2-Based ...

Summary by Enid News & Eagle

Focus on the discovery of next-generation LRRK2 inhibitors to unlock novel biological mechanisms of action and advance new treatment options

2 Articles

All

Left

Center

Right

Focus on the discovery of next-generation LRRK2 inhibitors to unlock novel biological mechanisms of action and advance new treatment options

4 days ago

Data from a Phase 1 study showed ION859 was generally well tolerated, and it reduced LRRK2 — a protein often overactive in Parkinson’s.

4 days ago

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Total News Sources2

Leaning Left1Leaning Right0Center0Last Updated3 days agoBias Distribution

100% Left

100% Left

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

Enid News & Eagle broke the news in 4 days ago on Tuesday, April 15, 2025.

Sources are mostly out of (0)